UNSPSC 51273006: Mepivacaine

This classification denotes an anesthetic agent with the molecular formula C15H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B6E06QE59J, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-methyl- but generally known as mepivacaine, which bears US NIH Compound Identifier 4062. European Medicines Agency schedules Mepivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14514MIG.

UNSPSC 51273006 Mepivacaine is a Commodity code that nominally identifies a local anesthetic pharmaceutical, yet the recent state and local opportunities posted under this code do not reflect mepivacaine procurement — instead, they capture broader pharmaceutical supply, drug deactivation systems, and prescription program infrastructure. State and local governments soliciting under this code are purchasing naloxone units, over-the-counter and generic multi-source pharmaceuticals, and pharmacy benefit program services through cooperative purchasing vehicles and direct health department procurement. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and state-led cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mismatch between the code's nominal scope and actual purchasing activity suggests either miscoding in the source opportunities or a drift in how the code is applied in practice; business development professionals should verify whether mepivacaine-specific demand exists independently of these posted solicitations.

Geographic concentration is limited to Florida, Texas, and Minnesota based on recent postings. Representative current opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2026) with quarterly deliveries to a county health facility, requiring vendors to include shipping and meet E-Verify compliance and standard insurance thresholds; the Texas HHS Commission's RFI (due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and MMCAP's RFP for generic and OTC pharmaceuticals (due March 26, 2026) through authorized wholesalers with pricing effective July 1, 2026, requiring cGMP certification, DSCSA compliance, and competitiveness weighting heavily on price at 75 percent. None of these solicitations explicitly targets mepivacaine as a line item.